Cell Therapies, Cancer & Rare Diseases

Cell Therapies, Cancer & Rare Diseases
  • Pininvest Analysis

Cell therapies have opened new treatment fields by cell inhibitors, gene modification, or even gene replacement

By gene modification after extraction of white blood cells from a leukemia-fighting patient, the cells are bolstered for more vigorous attack of cancer cells and reinjected in the patient; the Novartis treatment researched by University of Pennsylvania has been approved by the FDA in August ’17 and more than 76 applications have been accepted for testing in this promising field, possibly extending the procedure to some forms of brain and lung cancer patients - Check our note "Immunotherapy by adaptive cell transfer (ACT)' for more information

Gene replacement aims disease caused by a single faulty gene and the first treatment, targeting vision loss due to genetic mutation, introduced by Spark Therapeutics, is the first of its kind to be approved by FDA (December ’17)

Read our notes

Cell Therapies, Cancer & Rare Diseases • Updated:

Name Ticker Exchange Sector Industry Currency Cur.Price Mkt.Cap Perf. Vol. Risk Contrib. MDD
 
Adaptimmune Therapeutics ADAP NASDAQ Health Care Biopharmaceuticals USD 5.39 703 M 444.4% 167%   6% -55%
Amgen Inc. AMGN NASDAQ Health Care Biopharmaceuticals USD 231.10 136 B 17.0% 37%   2% -24%
Bellicum Pharmaceuticals BLCM NASDAQ Health Care Biopharmaceuticals USD 6.10 31 M -24.3% 130%   6% -85%
bluebird bio, Inc. BLUE NASDAQ Health Care Biopharmaceuticals USD 55.00 3.1 B -39.9% 66%   4% -59%
Cellectis (ADR) CLLS NASDAQ Health Care Gene Editing - Cell Therapies USD 18.08 768 M 73.7% 78%   4% -60%
Celyad (ADR) CYAD NASDAQ Health Care Biopharmaceuticals USD 8.41 117 M -10.2% 98%   4% -67%
Clovis Oncology, Inc. CLVS NASDAQ Health Care Biopharmaceuticals USD 5.73 440 M 66.4% 131%   6% -77%
Corvus Pharmaceuticals CRVS NASDAQ Health Care Biopharmaceuticals USD 4.03 113 M 15.1% 124%   5% -71%
CRISPR Therapeutics CRSP NASDAQ Health Care Gene Editing - Cell Therapies USD 106.70 6.5 B 166.4% 66%   4% -54%
Editas Medicine EDIT NASDAQ Health Care Gene Editing - Cell Therapies USD 33.18 1.8 B 62.2% 73%   5% -55%
Gilead Sciences GILD NASDAQ Health Care Biopharmaceuticals USD 60.55 76 B -3.1% 38%   1% -26%
Immunogen IMGN NASDAQ Health Care Biopharmaceuticals USD 5.25 916 M 95.9% 99%   5% -69%
Intellia Therapeutics NTLA NASDAQ Health Care Gene Editing - Cell Therapies USD 24.35 1.3 B 114.5% 85%   5% -47%
Intercept Pharmaceuticals ICPT NASDAQ Health Care Biopharmaceuticals USD 30.38 1.0 B -55.2% 86%   4% -76%
Invitae NVTA NYSE Health Care Gene Editing - Cell Therapies USD 47.24 5.9 B 166.3% 99%   6% -72%
MacroGenics MGNX NASDAQ Health Care Biopharmaceuticals USD 23.19 1.1 B 103.9% 149%   6% -27%
NantKwest, Inc. NK NASDAQ Health Care Biopharmaceuticals USD 8.45 832 M 661.3% 143%   6% -59%
Neos Therapeutics NEOS NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 0.58 29 M -59.8% 79%   3% -75%
Novartis NVS NYSE Health Care Drug Manufacturers - Diversified USD 85.69 194 B 2.5% 28%   1% -26%
Regeneron Pharmaceuticals REGN NASDAQ Health Care Biopharmaceuticals USD 576.63 65 B 93.5% 42%   2% -17%
REGENXBIO RGNX NASDAQ Health Care Gene Editing - Cell Therapies USD 27.03 1.0 B -31.3% 74%   4% -60%
Sangamo Therapeutics SGMO NASDAQ Health Care Gene Editing - Cell Therapies USD 10.60 1.5 B 25.1% 71%   4% -57%
uniQure QURE NASDAQ Health Care Gene Editing - Cell Therapies USD 39.07 1.7 B -10.0% 62%   3% -53%
Vericel VCEL NASDAQ Health Care Gene Editing - Cell Therapies USD 20.72 935 M 30.9% 66%   3% -62%
ZIOPHARM Oncology ZIOP NASDAQ Health Care Biopharmaceuticals USD 2.43 521 M -41.3% 79%   4% -64%